Dynamiker Biotechnology (Tianjin) Co., Ltd.

Dynamiker Biotechnology (Tianjin) Co., Ltd. was founded in early 2014, a high-tech enterprise integrated with R&D, production and sales globally. It is focused on developing early, rapid and innovative in vitro diagnostics of invasive fungal diseases (IFD). The company is located at the Sino-Singapore Tianjin Eco-city in Tianjin Binhai New Area.

R&D Team

By adhering to the principle of “Technology is Power”, the R&D team is consisted of domestic and overseas talented experts specialized in microbiology, immunology, molecular biology and clinical chemistry. Dr. Zeqi Zhou, who serves as the CTO of the team, obtained Ph.D. from Ohio University and Postdoctoral training at Harvard Medical School. Having the extensive experience gained at Bayer and Wyeth, he led the R&D team and successfully developed over 10 new IFD products that show strong competitiveness in the global market.

Market Development

Dynamiker’s goal is to “shape company’s brand with quality and explore world’s market with innovation”. Over 10 of the company’s newly developed IFD kits have recently been CE marked. Dynamiker products have already penetrated the domestic market national-wide. Globally, Dynamiker products have entered into 26 countries in Asia, Europe, the Americas and Africa.

Customer Service

High quality is essential for market development and customer satisfaction. Dynamiker focuses on the needs of clients and continuously improves its quality of after-sales service. With the establishment of four-level after-sales service support system, including clinical centers, distributor’s technical support team, Dynamiker’s customer service team as well as R&D team, we have gained the trust and support from our customers.

Our Vision

Looking ahead, all of us are full of confidence and dynamics. Dynamiker will continue to uphold our enterprise spirit of “Unity, Practicability, Openness and Innovation”. We are working together to make our company as a leader in IFD-IVD field and business market, to create an innovative national brand and have IPO launched in 5 years.

  • 2016-07-27 Dynamiker obtain a rewarding experience on ECCMID

    During 9-12th April 2016, annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) was successfully held in Amsterdam, the Netherlands.ECCMID is the largest well-known international conference in clinical microbiology and anti-infection field, providing an opportunity for the world’s leading experts, clinicians, clinical microbiologists and immunologists to discuss the latest developments and research achievements.Dynamiker Biotechnology, based on profound technical capability and reliable quality of products, was widely approved by microbiologists and distributors around the globe. In particular, Dynamiker Fungal Panel Testing attracted attention of experts from Germany, Finland, Belgium, Russia, Brazil and India.In Spain, Dynamiker Aspergillus Galactomannan Assay (GM assay) was twice evaluated with Bio-Rad Platelia Aspergillus antigen assay. The results exhibited that Dynamiker GM assay was completely coincident with Bio-Rad product. According to the excellent performance, Dynamiker Biotechnology was successfully signed a contract with Vircell (a famous Spanish company focusing on microbiology), indicating the beginning of Dynamiker in Spanish market after UK, France and Benelux. Dynamiker will continue contributing to accurate diagnosis and treatment of global fungal diseases with its slogan “Technology is Life”.

  • 2016-07-22 Evaluation Reports of Dynamiker G and GXM Assay Get Approved on ECCMID

    ECCMID is a yearly event that provides opportunity for the world’s leading experts and scholars come together and discuss the latest developments in infectious diseases, infection control and clinical microbiology. On the 26th ECCMID conference, Peking Union Medical College Hospital published two clinical evaluation reports based on Dynamiker G and GXM assay, respectively.One of the topic “Performance of Dynamiker® (1-3)-beta-D glucan assay compared to Fungitell® for the diagnosis of invasive fungal diseases from serum samples” reported clinical evaluation results by the comparison between Dynamiker Fungus (1-3)-beta-D glucan assay (G assay) and ACC Fungitell Assay. The total coincidence rate of two assays was 88.9%. The report was recommended to present as oral presentation and the number was 0141 which can be referred from the following website:http://eccmidlive.org/#resources/performance-of-dynamiker-1-3-beta-d-glucan-assay-compared-to-fungitell-for-the-diagnosis-of-invasive-fungal-diseases-from-serum-samplesAnother topic was “Comparison of an enzyme-linked immunosorbent assay and a latex agglutination test of cryptococcal antigen test on cerebrospinal fluid and serum”, published a total coincidence rate of 93.9% from the comparison between Dynamiker Cryptococcus neoformans Antigen assay (GXM assay) and IMMY Cryptococcus latex agglutination test. The report further demonstrated that, by using cerebrospinal fluid (CSF) as samples, Dynamiker GXM assay exhibited more advantages than IMMY Cryptococcus latex agglutination test towards result identification and disease detection. This report was presented as poster presentation with a number of P1645 that can be found in the website below: http://eccmidlive.org/#resources/comparison-of-an-enzyme-linked-immunosorbent-assay-and-a-latex-agglutination-test-of-cryptococcal-antigen-test-on-cerebrospinal-fluid-and-serumDynamiker Biotechnology, in accordance to superior clinical evaluation results, has achieved wide concern and approval by users from home and abroad. As specialise in diagnosis of invasive fungal disease (IFD), Dynamiker will continue in exploration and innovation, ensure the high quality of products, and establish competitive edge in domestic and foreign markets with core technology.

  • 2016-07-20 Dynamiker International Team on AAA conference, UK

    On 3-5th March 2016, Dynamiker international team attended the 7th Advances Against Aspergillosis conference (AAA) held in Manchester, UK. AAA conference has become the leading global meeting focusing on basic and clinical science of Aspergillus, and will make efforts to be a foundation of the knowledge repository regards to this pathogen.Professor Iain D. Page from the University of Manchester gave a poster presentation on topic “Comparative efficacy of six Aspergillus-specific IgG assays for the diagnosis of allergic bronchopulmonary aspergillosis (ABPA)”, which presented six global advanced products for Aspergillus antibody IgG detection including product from Dynamiker Biotechnology.Cardiff reference laboratory evaluated Dynamiker Fungus (1,3)-β-D-Glucan Assay and the reported results were widely approved by experts in various academic fields. The evaluation fully exhibited the competitiveness of our products. Dynamiker Biotechnology as a national enterprise on AAA conference exhibits strong international influence in fungal detection field, which also increases the popularity and reputation of national brand in intra-industry.

  • 2016-07-15 Dynamiker Biotechnology attend Serbia Diagnosis and Treatment of Fungal Diseases Symposium

    On February 26-27 2016, Dynamiker’s distributors in Serbia were invited to attend a symposium on the diagnosis and treatment of fungal diseases hosted by Serbia Society of Mycologists with the support of the ECMM.The symposium is of great value to Dynamiker in developing the Former Yugoslavia markets or even the whole European markets. During symposium, a number of experts are strongly interested in Dynamker fungal detection products, and speak highly of Dynamiker Fungal Panel Testing approach. Their support will be a solid foundation for Dynamiker to further expand the overseas market.

Add:14th building, Ecological Science Park, No. 2018 Zhongtian Revenue, Eco-City, TEDA, Tianjin 300467, P. R. China

Fax:0086-022 25264212


The Official QR Code

Scanning our official qr code, and record the related information of us. We look forward to your attention!

Latest Notices